These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27997433)

  • 1. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists.
    Hou JK; Kramer JR; Richardson P; Sansgiry S; El-Serag HB
    Inflamm Bowel Dis; 2017 Feb; 23(2):254-260. PubMed ID: 27997433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.
    Qumseya BJ; Ananthakrishnan AN; Skaros S; Bonner M; Issa M; Zadvornova Y; Naik A; Perera L; Binion DG
    Inflamm Bowel Dis; 2011 Jan; 17(1):77-83. PubMed ID: 20848501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
    Sousa M; Ladeira I; Ponte A; Fernandes C; Rodrigues A; Silva AP; Silva J; Gomes C; Afeto E; Carvalho J
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1099-1102. PubMed ID: 31206406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Indeterminate Rates Associated With Use of the QuantiFERON-TB Gold In-Tube Test in Children With Inflammatory Bowel Disease on Long-term Infliximab.
    Vortia E; Uko VE; Yen-Lieberman B; Frawley J; Worley SE; Danziger-Isakov L; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2018 Mar; 24(4):877-882. PubMed ID: 29562270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy.
    Vaughn BP; Doherty GA; Gautam S; Moss AC; Cheifetz AS
    Inflamm Bowel Dis; 2012 Jun; 18(6):1057-63. PubMed ID: 21953829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
    Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of vedolizumab in a patient with Crohn's disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report.
    Sugiyama Y; Ueno N; Tachibana S; Kobayashi Y; Murakami Y; Sasaki T; Sakatani A; Takahashi K; Ando K; Kashima S; Moriichi K; Tanabe H; Okumura T; Fujiya M
    Medicine (Baltimore); 2023 Jul; 102(28):e34331. PubMed ID: 37443475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.